Dear PGM Capital’s Blog reader, On Thursday, May 30, Bank of America – Merrill Lynch downgraded Teva Pharmaceutical (NYSE: TEVA) to underperform from Buy, and putting a price target on the stock to US$9 from US$19, causing yet another sell-off. Based on this downgrade, the stock price of company lost approx. 21% of its value[…]